Abstracts tagged "Myopathies"

Abstract Number: 0156 • ACR Convergence 2022
Impact of Polymyositis and Dermatomyositis in Patients Admitted with Congestive Heart Failure: An Insight from the National Database
Brinda Basida¹, Sanket Basida², Jasleen Kaur³, Urja Nagadia², mahmoud mansour², Palak Shah⁴ and Monil Majmundar⁵, ¹DMC/Sinai Grace Hospital, Detroit, MI, ²University of Missouri, Columbia, MO, ³DMC/WSU, Saginaw, MI, ⁴Metropolitan Hospital Center, New York Medical College, New York, NY, ⁵University of Kansas Medical Center, Kansas City, KS
Background/Purpose: Polymyositis (PM) and Dermatomyositis (DM) are systemic autoimmune diseases of inflammatory infiltrates in skeletal muscle resulting in chronic muscle weakness. Systemic involvement of the…
Abstract Number: 1882 • ACR Convergence 2022
Efficacy of Immune-apheresis in Patients with Inflammatory Myopathies: A Case Series
Kastriot Kastrati¹, Hanien Rajab², Anna Rader², Elisabeth Anna Aichner², Thomas Karonitsch², Hans-Peter Kiener², Michael Bonelli³, Daniel Aletaha⁴ and Helga Radner³, ¹Division of Rheumatology, Vienna, Austria, ²Medical University Vienna, Vienna, Austria, ³Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, ⁴Medical University Vienna, Wien, Austria
Background/Purpose: Idiopathic inflammatory myopathies (IIM) comprise a heterogenous group of acquired autoimmune diseases characterised by inflammation of muscle and affection of other organs, including lung…
Abstract Number: 0164 • ACR Convergence 2022
Anti-SSa/SSb and Ro52 Status and Pulmonary Function Tests in Patients with Interstitial Lung Disease and Idiopathic Inflammatory Myopathies
Abdullah Ahmed¹, Sonali Narain², Ivana Ilic¹, Can Hu³, Jaspreet Bhatti⁴ and Galina Marder⁵, ¹Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Manhasset, NY, ²Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ³Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Fort Lee, NJ, ⁴Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New York, NY, ⁵Donald and Barbara Zucker School of Medicine at Hofstra/ Northwell, Great Neck, NY
Background/Purpose: Interstitial lung disease (ILD) is a major cause of morbidity and mortality in patients with idiopathic inflammatory myositis (IIM). Anti-SSa/SSb and Ro52 are frequently…
Abstract Number: 1884 • ACR Convergence 2022
Idiopathic Inflammatory Myopathies in Alaska Native/American Indian People in Alaska
Vivek Mehta and Elizabeth Ferucci, Alaska Native Tribal Health Consortium, Anchorage, AK
Background/Purpose: Racial disparities have been in noted in various autoimmune disorders. Indigenous North American populations have higher prevalence and severity of a number of autoimmune…
Abstract Number: 0166 • ACR Convergence 2022
Detection of the Novel Autoantibodies Against Transcription Factor Sp4 Is Related with Low Risk of Cancer in Idiopathic Inflammatory Myopathy Patients
Yuji Hosono¹, Azusa Kojima¹, Akira Ishii¹, Mai Sugiyama¹, Yuto Izumi¹, Noriko Sasaki², Chiho Yamada¹ and Shinji Sato¹, ¹Tokai University School of Medicine, Isehara Kanagawa, Japan, ²Tokai University School of Medicine, sagamihara-city, Japan
Background/Purpose: In idiopathic inflammatory myopathy (IIM), many kinds of autoantibodies are often detected and associated with each clinical phenotype. Recently, autoantibody against transcription factor Sp4…
Abstract Number: 1886 • ACR Convergence 2022
Statin-induced Immune-mediated Miopathy: Treatment with Glucocorticoid-free Protocols and Role of Muscle Biopsy in the Follow-up
David Martínez-López¹, Piotr Szczęsny², Inger Nennesmo³, Karina Gheorghe⁴, Antonella Notarnicola⁵, Helene Alexanderson⁶, Ingrid Lundberg⁷ and Maryam Dastmalchi⁸, ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Department of Rheumatology, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland. Department of Neurology, Medical University of Warsaw, Warsaw, Poland, ³Department of Pathology, Karolinska University Hospital,Pathology, Karolinska University Hospital., Stockholm, Sweden, ⁴Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet. Rheumatology, Karolinska University Hospital Stockholm, Sweden. Center for Molecular Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ⁵Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ⁶Karolinska Institutet, Stockholm, Sweden, ⁷Karolinska Universitetssjukhuset, Karolinska Institutet, Stockholm, Sweden, ⁸Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Statin-induced immune mediated necrotizing myopathy (IMNM) is a recently identified autoimmune condition associated with anti-3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) antibodies, characterized by progressive muscle weakness leading…
Abstract Number: 0171 • ACR Convergence 2022
Cardiac Involvement in Idiopathic Inflammatory Myopathies: When Should We Look for It?
Matilde Bandeira¹, Eduardo Dourado¹, Ana Teresa Melo¹, Patricia Martins², Vanessa Fraga³, José Luís Ferraro⁴, André Saraiva⁵, Marlene Sousa⁶, Hugo Parente⁷, Catarina Soares⁸, Ana Margarida Correia⁹, Diogo Esperança Almeida⁹, Sara Paiva Dinis¹⁰, Ana Pinto¹¹, Filipe Pinheiro¹², Maria Rato¹², Tiago Beirão¹³, Beatriz Samões¹³, Bernardo Santos¹⁴, Carolina Mazeda¹⁵, Ana Teodósio Chícharo¹⁶, Margarida Faria¹⁷, Agna Neto¹⁷, Helena Lourenço¹⁸, Luísa Brites¹⁹, Marília Rodrigues¹⁹, Joana Silva-Dinis²⁰, João Madruga-Dias²¹, Filipe Araújo²², Nádia Martins²³, Maura Couto²³, Ana Valido²⁴, Maria José Santos²⁵, Sofia Barreira¹, João Eurico Fonseca¹ and Raquel Campanilho-Marques¹, ¹Serviço de Reumatologia, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Medicina de Lisboa (CAML), Lisboa, Portugal; Unidade de Investigação em Reumatologia, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, CAML, Lisboa, Portugal, ²Rheumatology department, Centro Hospitalar e Universitário de Lisboa Norte, Centro Académico de Medicina de Lisboa, Lisboa, Portugal, ³Serviço de Reumatologia, Hospital Beatriz Ângelo, Almada, Portugal, ⁴Serviço de Reumatologia, Hospital Beatriz Ângelo, Loures, Portugal, ⁵Rheumatology department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, ⁶Serviço de Reumatologia, Centro Hospitalar Universitário de Coimbra, Coimbra, Portugal, ⁷Rheumatology department, Unidade Local de Saúde do Alto Minho, Ponte de Lima, Portugal, ⁸Rheumatology department, Unidade Local de Saúde do Alto Minho, Ponte de Lima, Viana do Castelo, Portugal, ⁹Serviço de Reumatologia, Hospital de Braga, Braga, Portugal, Braga, Portugal, ¹⁰Rheumatology department, Unidade Local de Saúde da Guarda - Hospital Sousa Martins, Guarda, Portugal, ¹¹Local Health Unit of Guarda, Barcelos, Portugal, ¹²Rheumatology Department, Centro Hospitalar Universitário de São João, Porto, Portugal, ¹³Rheumatology Department, Centro Hospitalar de Vila Nova de Gaia / Espinho, Vila Nova de Gaia, Portugal, ¹⁴Serviço de Reumatologia, Centro Hospitalar do Baixo Vouga, Aveiro, Portugal, ¹⁵Centro Hospitalar Baixo Vouga, Ovar, Portugal, ¹⁶Serviço de Reumatologia, Centro Hospitalar Universitário do Algarve, Faro, Portugal, ¹⁷Serviço de Reumatologia, Hospital Nélio Mendonça, Serviços de Saúde da Região Autónoma da Madeira, Funchal, Portugal, ¹⁸Serviço de Reumatologia, Centro Hospitalar de Lisboa Ocidental, Lisboa, Portugal, ¹⁹Serviço de Reumatologia, Centro Hospitalar de Leiria, Leiria, Portugal, Leiria, Portugal, ²⁰Serviço de Reumatologia, Centro Hospitalar Universitário de Lisboa Central, Lisboa, Portugal, ²¹Rheumatology Service, Centro Hospitalar Médio Tejo, Tomar, Portugal, ²²Rheumatology and Osteoporosis Unit, Hospital de Sant´Ana, SCML, Lisboa, Portugal, ²³Rheumatology department, Centro Hospitalar Tondela-Viseu, Viseu, Portugal, ²⁴Serviço de Reumatologia, Unidade Local de Saúde do Litoral Alentejano, Santiago do Cacém, Portugal, ²⁵Hospital Garcia de Orta, Almada, Charneca da Caparica, Portugal
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a group of rare disorders that can affect the heart. It is unclear which patients are at higher risk.…
Abstract Number: 2237 • ACR Convergence 2022
Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Subcutaneous Abatacept in Adults with Active Idiopathic Inflammatory Myopathy: Results of the 24-Week Double-Blind and 28-Week Open-Label Periods
Rohit Aggarwal¹, Ingrid Lundberg², Yeong-Wook Song³, Aziz Shaibani⁴, Victoria Werth⁵ and Michael Maldonado⁶, ¹Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, ²Karolinska Universitetssjukhuset, Karolinska Institutet, Stockholm, Sweden, ³Seoul National University, Seoul, Republic of Korea, ⁴Nerve and Muscle Center of Texas, Houston, TX, ⁵Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, ⁶Bristol Myers Squibb, Princeton, NJ
Background/Purpose: A 52-week (wk), randomized, placebo (PBO)-controlled phase 3 trial of subcutaneous (SC) abatacept (ABA) and standard of care (SOC) was performed in patients (pts)…
Abstract Number: 0175 • ACR Convergence 2022
Extracorporeal Membrane Oxygenation for Acute Lung Injury in Idiopathic Inflammatory Myopathies – a Potential Lifesaving Intervention
boyang zheng¹, Ellen Eline², Lilian Xu³, Kun Huang⁴, Greet Hermans⁵, michael Perch⁶, gordan Samoukovic¹, ellen De Langhe⁵, Maryam Dastmalchi⁷, Lisa Christopher-Stine², Louise Diederichsen⁸ and Valerie Leclair¹, ¹McGill University, Montréal, QC, Canada, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴University of British Columbia, Vancouver, BC, Canada, ⁵University Hospitals Leuven, Leuven, Belgium, ⁶Righospitalet, University of Copenhagen, Copenhagen, Denmark, ⁷Karolinska University Hospital, Stockholm, Sweden, ⁸Copenhagen University Hospital, Rigshospitalet, Dragør, Denmark
Background/Purpose: Idiopathic inflammatory myopathies (IIM) can present with acute IIM-related lung injury and respiratory failure, leading to a high mortality risk in intensive care units…
Abstract Number: 2242 • ACR Convergence 2022
Metabolomics-based Identification of Metabolic Dysfunction in Inclusion Body Myositis
Jemima Albayda¹, Cissy Zhang¹, Pratik Khare¹, Brittany Adler¹, Erika Darrah¹, Lisa Christopher-Stine¹, Thomas E Lloyd² and Anne Le¹, ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Sporadic Inclusion Body Myositis (IBM) is the most common myopathy over the age of 50 and is currently refractory to treatment. The pathogenesis of…
Abstract Number: 0176 • ACR Convergence 2022
Diagnostic Accuracy and Clinical Relevance of Muscle Biopsy in Patients with Suspected Myositis
Kastriot Kastrati¹, Nasim NAKHOST LOTFI², Marwa Tawfik³, Ellen Gelpi², Romana Hoeftberger², Hans-Peter Kiener², Daniel Aletaha⁴, Michael Bonelli⁵ and Helga Radner⁵, ¹Division of Rheumatology, Vienna, Austria, ²Medical University Vienna, Vienna, Austria, ³Suez Canal University, Ismailia, Egypt, ⁴Medical University Vienna, Wien, Austria, ⁵Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
Background/Purpose: Diagnosis of idiopathic inflammatory myopathies (IIM) represents a clinical challenge and muscle biopsy is regarded as a fundamental procedure for confirming diagnosis. However, the…
Abstract Number: 0441 • ACR Convergence 2021
A Randomized, Double-blind, Placebo-controlled Study of Arimoclomol in Patients with Inclusion Body Myositis
Pedro Machado¹, Richard Barohn², Michael McDermott³, Thomas Blaetter⁴, Tom Lloyd⁵, Aziz Shaibani⁶, Miriam Freimer⁷, Anthony Amato⁸, Emma Ciafaloni³, Sarah Jones⁹, Tahseen Mozaffar¹⁰, Summer Gibson¹¹, Matthew Wicklund¹², Todd Levine¹³, Claus Sundgreen⁴, Tim Carstensen⁴, Karen Bonefeld⁴, Anders Jørgensen⁴, Karina Phonekeo⁴, Andrew Heim¹⁴, Laura Herbelin¹⁴, Michael Hanna¹⁵ and Mazen Dimachkie¹⁴, ¹Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, ²University of Missouri - Columbia, Columbia, MO, ³University of Rochester, Rochester, NY, ⁴Orphazyme A/S, Copenhagen, Denmark, ⁵Johns Hopkins University, Baltimore, MD, ⁶Nerve and Musle Center, Houston, TX, ⁷Ohio State University, Columbus, OH, ⁸Brigham and Women's Hospital, Boston, MA, ⁹University of Virginia, Charlottesville, VA, ¹⁰University of California Irvine, Irvine, CA, ¹¹University of Utah, Salt Lake City, UT, ¹²University of Colorado, Denver, CO, ¹³Phoenix Neurological Associates, Phoenix, AZ, ¹⁴University of Kansas Medical Center, Kansas City, KS, ¹⁵University College London, London, United Kingdom
Background/Purpose: Inclusion body myositis (IBM) is the most common idiopathic inflammatory myopathy occurring in patients over the age of 45 years. Since immune suppression has…
Abstract Number: 0443 • ACR Convergence 2021
Safety and Efficacy of Belimumab in the Treatment of Adult Idiopathic Inflammatory Myositis (Polymyositis and Dermatomyositis)
Priyal Chadha¹, Sonali Narain², Preeya Nandkumar³, Cristine Sison⁴, Elena Schiopu⁵, Todd Levine⁶, James Tsang⁷ and Galina Marder⁸, ¹SUNY Upstate Medical University, Syracuse, NY, ²Northwell Health, Great Neck, NY, ³Division of Rheumatology, Department of Medicine, Northwell, Great Neck, NY, ⁴Biostatistics Unit , Department of Molecular Medicine, Feinstein Institutes for Medical Research at Northwell Health, Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ⁵University of Michigan, Ann Arbor, MI, ⁶Phoenix Neurological Associates, Phoenix, AZ, ⁷Center for Research Informatics & Innovation (CRII), Feinstein Institute for Medical Research at Northwell Health, Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ⁸Division of Rheumatology, Department of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY
Background/Purpose: Treatment of Idiopathic Inflammatory Myositis (IIM) includes steroids and immunosuppressive agents. Targeting IL6, IL1, TNF for treatment of IIM has not been successful, and…
Abstract Number: 0697 • ACR Convergence 2021
Detection of Autoantibodies Against Muscle-Specific Four-and-a-Half-LIM Domain 1 (FHL1) in Inflammatory Myopathies: Results from a Single-Center Cohort
Angeles Shunashy Galindo-Feria¹, Begum Horuluoglu¹, Jessica Day², Catia Cerqueira³, Edvard Wigren⁴, Susanne Gräslund⁴, Susanna Proudman⁵, Ingrid E Lundberg⁴ and Vidya Limaye⁶, ¹Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ²Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia and Discipline of Medicine, University of Adelaide, Adelaide, Australia, ³4Dcell, Montreuil, France, ⁴Karolinska Institutet, Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, Stockholm, Sweden, ⁵University of Adelaide, Medindie, Australia, ⁶Royal Adelaide Hospital, Adelaide, Australia
Background/Purpose: Autoantibodies targeting a muscle-specific autoantigen, four-and-a-half-LIM-domain 1 (FHL1), have been previously identified in patients with idiopathic inflammatory myopathies (IIM) (1). The aim of this…
Abstract Number: 0701 • ACR Convergence 2021
Use and Yield of Computed Tomography as a Cancer Surveillance Method in Idiopathic Inflammatory Myositis
Christopher Mecoli¹, Brant Chee², XingYao Wang³, Mengkun Chen⁴, William Kelly³, Elizabeth Platz⁴, Livia Casciola-Rosen⁵, Lisa Christopher-Stine³ and Ami Shah⁶, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Applied Physics Laboratory, Baltimore, MD, ³Johns Hopkins University, Baltimore, MD, ⁴Johns Hopkins School of Public Health, Baltimore, MD, ⁵Johns Hopkins, Baltimore, MD, ⁶Johns Hopkins Rheumatology, Baltimore, MD
Background/Purpose: To inform guidance for cancer surveillance in patients with idiopathic inflammatory myositis (IIM), we conducted a retrospective cohort study in a single tertiary referral…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].